Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
JAMA Oncology
|
May 15, 2025
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial
John Nikitas, Leslie K Ballas, Tahmineh Romero, et al.
European Urology Oncology
|
March 4, 2023
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography
Clayton P Smith, James A Proudfoot, Paul C Boutros, et al.
European Urology
|
September 20, 2024
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium
Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, et al.
European Urology Oncology
|
February 19, 2021
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging
Ting Martin Ma, Andrei Gafita, David Shabsovich, et al.
European Urology
|
October 1, 2025
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial
Amar U Kishan, Jesus E Juarez Casillas, Paul Sargos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 14, 2021
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond
Ting Martin Ma, Soumyajit Roy, Xue Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
JAMA Network Open
|
December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis
Ting Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
The Lancet. Oncology
|
January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Holly Hartman, et al.
Lancet (London, England)
|
March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Christopher C Parker, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
JAMA Oncology
|
May 15, 2025
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial
John Nikitas, Leslie K Ballas, Tahmineh Romero, et al.
European Urology Oncology
|
March 4, 2023
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography
Clayton P Smith, James A Proudfoot, Paul C Boutros, et al.
European Urology
|
September 20, 2024
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium
Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, et al.
European Urology Oncology
|
February 19, 2021
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging
Ting Martin Ma, Andrei Gafita, David Shabsovich, et al.
European Urology
|
October 1, 2025
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial
Amar U Kishan, Jesus E Juarez Casillas, Paul Sargos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 14, 2021
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond
Ting Martin Ma, Soumyajit Roy, Xue Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U Kishan, Luca F Valle, Holly Wilhalme, et al.
JAMA Network Open
|
December 29, 2021
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis
Ting Martin Ma, Tahmineh Romero, Nicholas G Nickols, et al.
The Lancet. Oncology
|
January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Holly Hartman, et al.
Lancet (London, England)
|
March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Amar U Kishan, Yilun Sun, Christopher C Parker, et al.
Page
of 8